Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT00905034
Phase
PHASE2
Status
Completed

Conditions

  • Leukemia, Lymphocytic, Acute

Eligibility Criteria

Sex
ALL
Age
1 Year - N/A
Healthy Volunteers
Not accepted

Interventions

  • Methotrexate — DRUG
    200 mg/m\^2 by vein on days 1 and 15.
  • Vincristine — DRUG
    1.4 mg/m\^2 by vein (maximum dose 2 mg) on days 1, 8 and 15.
  • PEG-l-asparaginase — DRUG
    2500 International units/m\^2 by vein on days 2 and 16
  • Dexamethasone — DRUG
    40 mg by vein or by mouth daily days 1-4 and 15-18.
  • Rituximab — DRUG
    Rituximab 375 mg/m\^2 by vein on days 1 and 15 (first 4 cycles) for patients CD20 positive or positive by immunostain.

Study Details

This goal of this clinical research study is to learn if the combination of methotrexate, pegylated-L-asparaginase, vincristine, and dexamethasone (also rituximab in some patients) can help to control ALL that has not responded to previous treatment or has come back after a response or chronic myeloid leukemia (CML).

Key Dates

Start date
Mar 31, 2009
Status verified
Jun 2015
Primary completion
Feb 28, 2015
Completion
Feb 28, 2015

Study Design

Enrollment
37 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: MOAD
    Chemotherapy regimen of methotrexate, rituximab, vincristine, pegylated L-asparaginase and dexamethasone (MOAD).

Primary Outcome Measure

Complete Response (CR) Rate [ Time Frame: 6 cycles (cycle = 28 days) ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Texas MD Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Houston, TX

By research site
University of Texas MD Anderson Cancer Center· Houston, TX

Related Studies